… In these studies, aggressive lipid lowering has been found to induce atherosclerotic lesion
stabilization or even regression and to reduce clinical cardiovascular events, although the …

… There is a large evidence base, supported by the WHO, for the use of statins as lipid-lowering
therapy for the prevention of further cardiovascular events. There is no similar guidance …

… cardiovascular disease and recurrent cardiovascular events. To this end, the ATP Ill panel
adapted the concept of coronary artery … intensive recommendations for lowering LDL-C levels. …

… In this population of patients with atherosclerotic cardiovascular disease, we found high
cardiovascular event rates, which increased with baseline LDL-C levels. Although most patients …

… in individuals receiving lipid-lowering therapy who experienced a CV event. This study had
… a CV event, to characterise lipid-modifying therapy that is used before and after a CV event …

… now shown that lowering LDL with non-statins reduces cardiovascular events. In ASCVD
patients on statins, adding ezetimibe or a PCSK9 inhibitor led to reductions in CV events in the …

… /l lower in those allocated atorvastatin compared with placebo. There were 116 (9.2%)
major cardiovascular events or procedures in the atorvastatin group and 151 (11.9%) events in …

… of lipid-associated cardiovascular events among patients optimally treated per guidelines
but who cannot achieve LDL-C goals and who could benefit from additional LDL-C-lowering …

… established as the primary lipid treatment target. Guidelines … In patients undergoing
hemodialysis, lipid abnormalities are … lowering as a means to lower cardiovascular events in the …

… In addition to reducing first events in patients after an acute coronary syndrome (ACS), we …
would also reduce recurrent cardiovascular events, and therefore total events, compared with …